COVID-19: Launch of national platform, FNR Call in the making
01 April 2020
As researchers work on numerous new projects to contribute to the fight against COVID-19, Research Luxembourg has launched a national COVID-19 platform to coordinate research projects and collaborations. The FNR will soon open a special fast-track Call for proposals to support research efforts.
The Luxembourg research community has reacted rapidly to the COVID-19 pandemic, creating also a need for coordination and collaboration. Research Luxembourg (University, LIH, LISER, LIST, FNR, Ministry of Higher Education and Research) has therefore launched a national COVID-19 platform. This website will support the research community, facilitate exchange and the identification of synergies.
On top of giving a good overview of COVID-19 research in Luxembourg, this centralised platform aims at fostering collaboration and communication.
The different parts of the platform allow researchers to:
- Submit project ideas
- Browse ongoing projects
- Browse submitted open ideas
- Share and discuss new ideas (under construction)
The Luxembourg National Research Fund (FNR) will shortly announce a special fast-track Call to provide initial funding for research projects on COVID-19, with a deadline of 9 April. The aim is to (co-)support short-term projects, or the starting phase of long-term projects. In order to be eligible for the FNR Call, short descriptions of project ideas must first be published on the COVID-19 platform.
Multiple Types of Long COVID Identified for the First TimeA consortium of Luxembourgish research institutions studying the national population have been looking to identify factors that may contribute to…
Physical activity to reduce the severity of COVID-19A consortium of Luxembourgish research institutions studying the national population have been looking to identify factors that may contribute to…
Superimmunity: A defence mechanism against COVID-19?Two years after the pandemic outbreak, researchers and scientists continue to look at the immune system’s defence mechanisms against the…
The why behind mild COVID-19From the start of the COVID-19 pandemic, the majority of published studies have focused on severe COVID-19 patients in order…
In conversation with our young researchers: Abir ElbéjiHow to better follow COVID-19-related symptoms thanks to new digital biomarkers and tools and how to improve Long Covid patients’…
Shedding light on COVID-19 – Presentation of CoVaLuxDespite the worldwide COVID-19 pandemic entering its third year, open questions pertaining to the occurrence of new variants, ensuing new…
Europe must come together to confront OmicronOmicron. The SARS-CoV-2 Omicron variant is spreading rapidly in Europe, even in countries with high levels of vaccination, including those…
What are the benefits, costs and feasibility of a low incidence COVID-19 strategyA low incidence strategy. Lifting some non-pharmaceutical interventions means living with a relatively high incidence of cases. Such a high…